<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289285</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI306B301</org_study_id>
    <nct_id>NCT04289285</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IBI306 in Chinese Subjects With Non-familiar Hypercholesterolemia</brief_title>
  <official_title>Safety and Efficacy of IBI306 in Chinese Non-familiar Hypercholesterolemia Subjects at Very High or High Cardiovascular Risk: a Randomized, Double-blind and Placebo-controlled Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBI306 is a fully human monoclonal antibody that binds proprotein convertase
      substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density
      lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and
      low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate
      the effects of IBI306 in Chinese people with non-familiar hypercholesterolemia with very high
      or high cardiovascular risk. This study will see if IBI306 will reduce low density
      lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of
      lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side
      effects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of IBI306
      in Chinese non-familiar hypercholesterolemia Subjects with very high or high cardiovascular
      risk. A total of 600 subjects who meet admission criteria will be randomized and receive one
      of the 3 dose levels of IBI306 or matching placebo: 450mg Q4W, 600mg Q6W or 600mg Q8W. The
      double blind period for the 450mg Q4W and 600mg Q6W groups will be 12 weeks, and for the
      600mg Q8W groups will be 16weeks. The study will last 52 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 12 or 16</measure>
    <time_frame>Week 12 or week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent of subjects with LDL-C reduction no less than 50% from baseline</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of subjects with LDL-C&lt;70mg/dL(1.8 mmol/L)</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in Lp(a),ApoB, non-HDL-c, ApoB/ApoA1 from baseline</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>IBI306 450mg SC Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI306 600mg SC Q6W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC Q6W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI306 600mg SC Q8W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC Q8W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI306 450mg SC Q4W</intervention_name>
    <description>Subjects will receive IBI306 450mg every 4 weeks subcutaneously.</description>
    <arm_group_label>IBI306 450mg SC Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC Q4W</intervention_name>
    <description>Subjects will receive placebo every 4 weeks subcutaneously.</description>
    <arm_group_label>Placebo SC Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI306 600mg SC Q6W</intervention_name>
    <description>Subjects will receive IBI306 600mg every 6 weeks subcutaneously.</description>
    <arm_group_label>IBI306 600mg SC Q6W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo SC Q6W</intervention_name>
    <description>Subjects will receive placebo every 6 weeks subcutaneously.</description>
    <arm_group_label>Placebo SC Q6W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI306 600mg SC Q6W</intervention_name>
    <description>Subjects will receive IBI306 600mg every 8 weeks subcutaneously.</description>
    <arm_group_label>IBI306 600mg SC Q8W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo SC Q8W</intervention_name>
    <description>Subjects will receive placebo every 8 weeks subcutaneously.</description>
    <arm_group_label>Placebo SC Q8W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Males and females ≥ 18 to ≤ 75 years of age

          2. Diagnosis of hypercholesterolemia

          3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)

          4. Very high or high cardiovascular risk

          5. TG≤500 mg/dL(5.64 mmol/L)

        Exclusion criteria:

          1. Diagnosis of HoFH or HeFH

          2. Uncontrolled hypertension

          3. Uncontrolled hyperthyroidism or hypothyroidism

          4. Severe renal dysfunction

          5. Known sensitivity to any of the products to be administered during dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Yu</last_name>
    <phone>86-18543019933</phone>
    <email>yang.yu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Huo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

